Medpace Insider Activity: Susan Burwig Exercises 10,000 Options

Rhea-AI Filing Summary

Susan E. Burwig, Executive Vice President, Operations at Medpace Holdings, Inc. (MEDP), exercised employee stock options to acquire 10,000 shares on 09/26/2025 at an exercise price of $107.93 per share. The filing states the option vested in full on 02/28/2020. The Form 4 lists 67,500 shares as the amount of common stock beneficially owned following the non-derivative transaction and lists 30,984 shares as the number of derivative securities beneficially owned following the derivative transaction. The form is signed by an attorney-in-fact on behalf of Ms. Burwig on 09/30/2025.

Positive

• Insider purchase reported: Executive exercised 10,000 options, showing continued executive ownership alignment with shareholders
• Vested options: The option vested on 02/28/2020, indicating the exercise was eligible and not a recent accelerated grant
• Filing completeness: Form 4 includes transaction date, price, vested-date explanation and attorney-in-fact signature

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider exercised 10,000 options at $107.93, indicating retained equity exposure; vesting occurred in 2020.

The exercise of 10,000 employee stock options at $107.93 increases the reporting persons share holdings and converts an in-the-money derivative into common stock. The filing confirms the option fully vested on 02/28/2020, so this transaction reflects routine post-vesting exercise rather than a new grant. The reported beneficial ownership figures (67,500 shares after the non-derivative transaction and 30,984 derivative securities after the derivative section) should be read as the values the filer provided; investors may reconcile these with company disclosures for clarity.

Corporate Governance Expert

TL;DR: This is a standard Form 4 reporting an option exercise by an officer, documented and signed via attorney-in-fact.

The filing identifies Ms. Burwig as an officer (Exec. VP, Operations) and reports the exercise of employee stock options that vested in 2020. Documentation appears complete with an attorney-in-fact signature. This is a routine insider transaction that provides transparency about executive equity ownership but does not by itself indicate a change in corporate control or governance policy.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

BURWIG SUSAN E

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Exec. VP, Operations

3. Date of Earliest Transaction (Month/Day/Year)
09/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/26/2025		M		10,000	A	$107.93	67,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$107.93	09/26/2025		M			10,000	(1)	02/28/2026	Common Stock	10,000	$0	30,984	D

Explanation of Responses:

1. The option vested in full on February 28, 2020.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Susan E. Burwig	09/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Susan E. Burwig report on Form 4 for MEDP?

She reported the exercise of an employee stock option to acquire 10,000 shares on 09/26/2025 at an exercise price of $107.93 per share.

What was the vesting date of the option exercised by the MEDP reporting person?

The filing states the option vested in full on 02/28/2020.

How many shares did the reporting person beneficially own after the transaction according to the Form 4?

The Form 4 lists 67,500 shares as beneficially owned following the non-derivative transaction and 30,984 as derivative securities beneficially owned following the derivative section.

What title does Susan E. Burwig hold at Medpace Holdings in the filing?

She is identified as Executive Vice President, Operations and is reported as an officer on the Form 4.

Who signed the Form 4 on behalf of the reporting person?

The Form 4 is signed by Stephen P. Ewald, Attorney-in-Fact for Susan E. Burwig on 09/30/2025.